The Pharmacoeconomics of Deep Vein Thrombosis Treatment

American Journal of Medicine

Volumn 120, Issue 10 SUPPL. 2, 2007, Pages

  Shorr, Andrew F ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Anticoagulation; Deep vein thrombosis; Pharmacoeconomics; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTICOAGULANTS; ENOXAPARIN; HUMANS; POLYSACCHARIDES; VENOUS THROMBOSIS;

EID: 34748852444     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.08.012     Document Type: Article

References (38)

1. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. de Lissovoy G. Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective. Am J Manag Care 7 suppl 17 (2001) S535-S538
3. Dranitsaris G., Kahn S.R., Stumpo C., et al. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. Am J Cardiovasc Drugs 4 (2004) 325-333
4. Jones T.E., Smith B.J., and Polasek J.F. Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin. Expert Opin Pharmacother 5 (2004) 1887-1897
5. Martel N., Lee J., and Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106 (2005) 2710-2715
6. Bergqvist D., Jendteg S., Johansen L., Persson U., and Odegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 126 (1997) 454-457
7. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) 401S-428S
8. Nutescu E.A., Shapiro N.L., Chevalier A., and Amin A.N. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 72 suppl 1 (2005) S2-S6
9. Siragusa S., Cosmi B., Piovella F., Hirsh J., and Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100 (1996) 269-277
10. van Dongen C.J., van den Belt A.G., Prins M.H., and Lensing A.W. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 4 (2004) CD001100
11. Spyropoulos A.C., Hurley J.S., Ciesla G.N., and de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 122 (2002) 108-114
12. Gould M.K., Dembitzer A.D., Sanders G.D., and Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 130 (1999) 789-799
13. Savi P., Chong B.H., Greinacher A., et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 105 (2005) 139-144
14. Reynolds N.A., Perry C.M., and Scott L.J. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs 64 (2004) 1575-1596
15. Buller H.R., Davidson B.L., Decousus H., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004) 867-873
16. Shorr A.F., Jackson W.L., Moores L.K., and Warkentin T.E. Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. J Thromb Thrombolysis 23 (2007) 229-236
17. Aujesky D., Smith K.J., Cornuz J., and Roberts M.S. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 128 (2005) 1601-1610
18. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
19. Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., and Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 130 (1999) 800-809
20. McGarry L.J., Thompson D., Weinstein M.C., and Goldhaber S.Z. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care 10 (2004) 632-642
21. Prandoni P., Siragusa S., Girolami B., and Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106 (2005) 3049-3054
22. Warkentin T.E., Cook R.J., Marder V.J., et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106 (2005) 3791-3796
23. Merli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134 (2001) 191-202
24. ARIXTRA. [package insert] (2005), GlaxoSmithKline, Research Triangle Park, NC
25. Davidson B.L., Buller H.R., Decousus H., et al. Outcomes in obese patients of pulmonary embolism and deep vein thrombosis treatment with fondaparinux or low-molecular-weight heparins: the MATISSE trials. Poster presented at the Annual Meeting of the International Society on Thrombosis and Haemostasis; August 5, 2005; Sydney, Australia (2005)
26. LOVENOX. [package insert] (2005), Aventis Pharmaceuticals Inc, Bridgewater, NJ
27. Innohep. [package insert] (2003), Pharmion Corporation, Boulder, CO
28. Michota F., and Merli G. Anticoagulation in special patient populations: are special dosing considerations required?. Cleve Clin J Med 72 suppl 1 (2005) S37-S42
29. Efird L.E., and Kockler D.R. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 40 (2006) 1383-1387
30. Harenberg J., Jorg I., and Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 89 (2004) 1017-1018
31. Kovacs M.J. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 93 (2005) 999-1000
32. Kuo K.H., and Kovacs M.J. Fondaparinux: a potential new therapy for HIT. Hematology 10 (2005) 271-275
33. Spruill W.J., Wade W.E., and Leslie R.B. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty. Am J Ther 11 (2004) 3-8
34. Sullivan S.D., Davidson B.L., Kahn S.R., Muntz J.E., Oster G., and Raskob G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 22 (2004) 605-620
35. Bauer K.A., Eriksson B.I., Lassen M.R., and Turpie A.G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345 (2001) 1305-1310
36. Shorr A.F., Jackson W.L., Weiss B.M., and Moores L.K. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis. Blood Coagul Fibrinolysis 18 (2007) 309-316
37. Knight K.K., Wong J., Hauch O., Wygant G., Aguilar D., and Ofman J.J. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 8 (2005) 191-200
38. Stein P.D., Hull R.D., Kayali F., Ghali W.A., Alshab A.K., and Olson R.E. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 164 (2004) 2260-2265